Epiminder Says US Clinical Study Evaluating Epilepsy Monitoring Platform Enrolls 75th Patient

MT Newswires Live

5小時前

Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.

The recruitment is in line with expectations and the firm remains on track to enroll 210 patients by end of the first half of 2027, the firm's Chief Executive Rohan Hoare said.

The study is evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy following an inconclusive prolonged electroencephalographic monitoring assessment.

The medical device company's shares rose nearly 2% in recent trading on Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2668322639"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668322639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668322639?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 09:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668322639","market":"hk","top_or_hot":-1,"title":"Epiminder Says US Clinical Study Evaluating Epilepsy Monitoring Platform Enrolls 75th Patient","media":"MT Newswires Live","content":"<html><body><p> Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.</p><p>The recruitment is in line with expectations and the firm remains on track to enroll 210 patients by end of the first half of 2027, the firm's Chief Executive Rohan Hoare said.</p><p>The study is evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy following an inconclusive prolonged electroencephalographic monitoring assessment.</p><p>The medical device company's shares rose nearly 2% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Epiminder Says US Clinical Study Evaluating Epilepsy Monitoring Platform Enrolls 75th Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEpiminder Says US Clinical Study Evaluating Epilepsy Monitoring Platform Enrolls 75th Patient\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-17 09:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.</p><p>The recruitment is in line with expectations and the firm remains on track to enroll 210 patients by end of the first half of 2027, the firm's Chief Executive Rohan Hoare said.</p><p>The study is evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy following an inconclusive prolonged electroencephalographic monitoring assessment.</p><p>The medical device company's shares rose nearly 2% in recent trading on Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPI.AU","symbol_name":"Epiminder Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668322639","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668322639","pubTimestamp":1789607394,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.The recruitment is in line with expectations and the firm remains on t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPI.AU":"Epiminder Limited","BK7007":"医疗保健设备"},"translate_title":"Epiminder 表示评估癫痫监测平台的美国临床研究招募了第 75 名患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPI.AU":1},"content_text":"Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.The recruitment is in line with expectations and the firm remains on track to enroll 210 patients by end of the first half of 2027, the firm's Chief Executive Rohan Hoare said.The study is evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy following an inconclusive prolonged electroencephalographic monitoring assessment.The medical device company's shares rose nearly 2% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}